Verastem, INC 8-K filings

Verastem Oncology announced positive updated safety and efficacy results from the RAMP 205 trial evaluating avutometinib plus defactinib in combination with chemotherapy for first-line metastatic pancreatic cancer.

Verastem, Inc. held its 2026 annual meeting where stockholders elected directors, approved equity and stock purchase plans, ratified auditor selection, and voted on executive compensation.

Verastem Oncology announced preliminary Q4 and full-year 2025 net product revenues for AVMAPKI FAKZYNJA CO-PACK, along with an extended cash runway into the first half of 2027 and key 2026 strategic priorities.

Verastem, Inc. announced significant progress in its oncology pipeline, including the commercial launch of AVMAPKI FAKZYNJA CO-PACK and promising clinical data for VS-7375, alongside robust Q3 2025 net product revenue of $11.2 million.

Verastem Oncology announced the discontinuation of its RAMP 203 clinical trial for advanced KRAS G12C-mutated NSCLC to prioritize other promising programs.

Verastem Oncology announced strategic leadership changes, including a new Chairman and President of Development, alongside the completion of patient enrollment for its RAMP 301 Phase 3 trial.

Verastem, Inc. announced the closing of an underwritten public offering of common stock and pre-funded warrants, raising approximately $96.9 million in net proceeds.

Verastem Oncology reported strong Q3 2025 net product revenue of $11.2 million for AVMAPKI FAKZYNJA CO-PACK and promising clinical progress across its oncology pipeline.

Verastem Oncology announced encouraging preliminary safety and anti-tumor activity data from the first two dose levels of its VS-7375 Phase 1/2a trial for KRAS G12D mutant solid tumors.

Verastem Oncology announced positive updated safety and efficacy data from its partner GenFleet Therapeutics' Phase 1/2 monotherapy study of GFH375 (VS-7375) in advanced KRAS G12D mutant pancreatic cancer patients in China.

Verastem, Inc. reports a strong commercial launch for AVMAPKI FAKZYNJA CO-PACK in KRAS-mutated recurrent LGSOC and positive clinical progress for its pipeline, including VS-7375 and combination therapies.

Verastem Oncology announced positive updated safety and efficacy data for its KRAS G12D inhibitor, VS-7375, in advanced non-small cell lung cancer from a China-based Phase 1/2 study.

Verastem Oncology presented encouraging clinical data from its RAMP 205 trial for metastatic pancreatic cancer and provided updates on its novel KRAS G12D inhibitor, VS-7375, following the recent FDA approval of AVMAPKI FAKZYNJA CO-PACK.

Verastem Oncology announces positive updated data from its partner GenFleet Therapeutics' Phase 1 study in China of GFH375 (VS-7375), an oral KRAS G12D inhibitor, showing promising overall response rates in patients with pancreatic and lung cancers.

Verastem Oncology reports promising updated data from its RAMP 205 trial, showing an 83% overall response rate in frontline metastatic pancreatic cancer patients treated with avutometinib and defactinib in combination with standard chemotherapy.

Verastem Oncology's AVMAPKI FAKZYNJA CO-PACK has been granted accelerated FDA approval as the first treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.

Verastem Oncology secures $75 million through a private placement to advance the launch of avutometinib and defactinib and further clinical research.

Verastem Oncology is preparing for a mid-2025 launch of avutometinib and defactinib as a potential first FDA-approved treatment for KRAS mutant recurrent Low-Grade Serous Ovarian Cancer (LGSOC).

Verastem, Inc. has exercised its option to acquire rights to a novel KRAS G12D inhibitor and is preparing for a potential mid-2025 launch of its avutometinib and defactinib combination for recurrent KRAS mutant Low-Grade Serous Ovarian Cancer (LGSOC).

Verastem, Inc. has appointed Matthew E. Ros as its new Chief Operating Officer, effective January 14, 2025.

Verastem Oncology has secured a $150 million debt refinancing with Oberland Capital and a strategic commercialization partnership with IQVIA to support the potential launch of its drug combination for recurrent low-grade serous ovarian cancer.

Verastem Oncology reported positive mature data from the RAMP 201 trial, showing promising results for the combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer, and is on track to complete its NDA submission in October 2024.

Verastem, Inc. has entered into an underwriting agreement for a public offering of common stock and warrants, expected to generate net proceeds of approximately $51.1 million.

Verastem has begun the rolling submission of a New Drug Application to the FDA for its combination therapy targeting recurrent low-grade serous ovarian cancer, while also providing updates on market opportunities and clinical trial data.

Verastem Oncology is progressing towards commercialization with its avutometinib and defactinib combination therapy, targeting RAS/MAPK pathway-driven cancers, particularly low-grade serous ovarian cancer.

Verastem Oncology has begun the rolling submission of a New Drug Application to the FDA for accelerated approval of avutometinib and defactinib combination for recurrent KRAS mutant low-grade serous ovarian cancer.

Verastem Oncology reports positive initial safety and efficacy results from its RAMP 205 trial, showing an 83% partial response rate in a cohort of patients with metastatic pancreatic cancer.

Verastem Oncology is making significant strides in developing novel therapies for RAS/MAPK pathway-driven cancers, highlighted by positive clinical trial results and strategic partnerships.

Verastem Oncology is set to begin a rolling submission for FDA approval of its avutometinib and defactinib combination for recurrent low-grade serous ovarian cancer in the first half of 2024, among other key milestones.

Verastem, Inc. stockholders approved a one-time exchange of certain stock options for new options at a special meeting held on January 17, 2024.